Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome
Open Access
- 25 January 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 111 (3) , 343-348
- https://doi.org/10.1161/01.cir.0000153272.48711.b9
Abstract
Background— The metabolic syndrome is associated with increased angiotensin II activity, induction of a proinflammatory and oxidative state, and endothelial dysfunction. We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antioxidant, to affect endothelial function and inflammation in patients with the metabolic syndrome.Keywords
This publication has 25 references indexed in Scilit:
- Epidemic Obesity and the Metabolic SyndromeCirculation, 2003
- C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular EventsCirculation, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cellsAtherosclerosis, 2001
- Novel mechanisms linking angiotensin II and early atherogenesisJournal of the Renin-Angiotensin-Aldosterone System, 2000
- Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?The American Journal of Cardiology, 1999
- Macrophages and atherosclerotic plaque stabilityCurrent Opinion in Lipidology, 1996
- Lipoic and Dihydrolipoic Acids as Antioxidants. a Critical EvaluationFree Radical Research, 1994
- The status of PAI-1 as a risk factor for arterial and thrombotic disease: A reviewAtherosclerosis, 1992
- Thioctic Acid and Dihydrolipoic Acid are Novel Antioxidants Which Interact With Reactive Oxygen SpeciesFree Radical Research Communications, 1991